Cargando…

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer

Anti-estrogen and anti-HER2 treatments have been among the first and most successful examples of targeted therapy for breast cancer (BC). However, the treatment of triple-negative BC (TNBC) that lack estrogen receptor expression or HER2 amplification remains a major challenge. We previously discover...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakkar, A., Wang, B., Picon-Ruiz, M., Buchwald, P., Ince, Tan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869778/ https://www.ncbi.nlm.nih.gov/pubmed/27120467 http://dx.doi.org/10.1007/s10549-016-3807-y

Ejemplares similares

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Heat shock factor 1 induces cancer stem cell phenotype in breast cancer cell lines
por: Wang, Bin, et al.
Publicado: (2015)

Endocan as a prognostic biomarker of triple-negative breast cancer
por: Sagara, Atsunobu, et al.
Publicado: (2016)

Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival
por: Oprea-Ilies, Gabriela, et al.
Publicado: (2012)

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy
por: Girgert, Rainer, et al.
Publicado: (2012)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
por: Mori, Hitomi, et al.
Publicado: (2019)

pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1
por: Yu, MingMing, et al.
Publicado: (2020)

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
por: Jansson, Sara, et al.
Publicado: (2018)

Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation
por: Vihervuori, H., et al.
Publicado: (2022)

A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
por: Tseng, Ling-Ming, et al.
Publicado: (2017)

Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
por: Siddappa, Chidananda M., et al.
Publicado: (2019)

Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
por: Park, Jihyun, et al.
Publicado: (2021)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer
por: Fan, Yu, et al.
Publicado: (2023)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
por: Kundu, Namita, et al.
Publicado: (2013)

Association of reproductive history with breast tissue characteristics and receptor status in the normal breast
por: Gabrielson, Marike, et al.
Publicado: (2018)

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
por: Walter, Katherine R., et al.
Publicado: (2018)

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
por: Wander, Seth A., et al.
Publicado: (2013)

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015)

Inflammatory breast cancer (IBC): clues for targeted therapies
por: Fernandez, Sandra V., et al.
Publicado: (2013)

Downregulation of miR-205 contributes to epithelial–mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1–RAGE signaling pathway
por: Wang, Ling, et al.
Publicado: (2019)

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion
por: Mazumdar, Abhijit, et al.
Publicado: (2016)

Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture
por: Manda, Katrin, et al.
Publicado: (2020)

Engineering targeted chromosomal amplifications in human breast epithelial cells
por: Springer, Simeon, et al.
Publicado: (2015)

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer
por: Tahiri, Andliena, et al.
Publicado: (2020)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
por: Mina, Alain, et al.
Publicado: (2017)

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
por: Friedland, Julie C., et al.
Publicado: (2013)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Co-expressed genes enhance precision of receptor status identification in breast cancer patients
por: Kenn, Michael, et al.
Publicado: (2018)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes
por: Teinturier, Romain, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ljpia5j5aanicv0qnr2bfnp7ds